Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response...

Descripción completa

Detalles Bibliográficos
Autores principales: Beasley, Georgia M, Nair, Smita K, Farrow, Norma E, Landa, Karenia, Selim, Maria Angelica, Wiggs, Carol Ann, Jung, Sin-Ho, Bigner, Darell D, True Kelly, Andrea, Gromeier, Matthias, Salama, April KS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057552/
https://www.ncbi.nlm.nih.gov/pubmed/33875611
http://dx.doi.org/10.1136/jitc-2020-002203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057552/
https://www.ncbi.nlm.nih.gov/pubmed/33875611
http://dx.doi.org/10.1136/jitc-2020-002203

Ejemplares similares